The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.
Glycotex said that GLYC-101 is being developed to stimulate and modulate the natural cascade of wound healing activities of several cell populations.
The product candidate is a topical gel to be applied directly on the wound surface.
The strategic priorities for GLYC-101 include wound healing following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers.